Saturday, April 5, 2014

Combination test predicts risk of prostate cancer recurrence

EUREKALERT – April 4, 2014– A new test using a prostate tumor's genetic characteristics and oxygen content taken from biopsy samples can predict which men are at high or low risk of their prostate cancer recurring with close to 80 percent accuracy. Researchers at Princess Margaret Cancer Center at the University of Toronto, unveiled the test today at the European Society for Radiotherapy and Oncology (ESTRO33) meeting in Vienna. The test was developed from an analysis of DNA taken from the tumors of 126 surgically treated men who were considered to have an intermediate risk of recurrence. Using a genomic DNA analysis technique they looked for missing, extra or irregular sections of DNA in the tumor samples and followed the men for an average of 7.8 years. From the men who recurred they were able to identify a genetic "signature" that predicted recurrence. In another study, they tested the oxygen content of the tumors from men treated with radiation therapy. When they combined the two tests they found that men with high levels of genetic changes and low levels of oxygen had worse outcomes, with 49 percent surviving for five years without recurrence. The researchers say it will take a few more years of testing in larger groups to fully validate the test.

No comments:

Post a Comment